SPEAKERS | Kisaco Research

SPEAKERS

Advanced Wound Care USA
15-16 July, 2025
Boston, USA

SUBMIT A SPEAKER FOR 2025

As the Advanced Wound Care Summit Series expands, we are keen to hear your feedback on whom you want to hear from within the industry.

If you have a speaker or content idea that you would like to suggest for our 2025 USA Summit please submit your suggestions below.

All applications will be reviewed and our team will be in touch if we have any further questions.

SUBMIT SUGGESTION

THANK YOU TO OUR OUTSTANDING 2024 SPEAKER FACULTY

-

  •

    Author:

    Mike Griffiths

    CEO & President
    Advanced Oxygen Therapy Inc

    Dr. Griffiths has worked in the critical and wound care fields for over three decades. He is a Fellow of both the Royal Society of Medicine and Chartered Management Institute. He holds a Doctorate from Middlesex University, London, United Kingdom, a post-graduate Diploma in Management from Kingston University, United Kingdom, and several further engineering and clinical credentials, including that of a Certified Respiratory Therapist.

    Dr. Griffiths is also a seasoned medical device executive who has been the CEO, President and Co-Founder of AOTI, since 2006. He brings his years of experience gained from a wide variety of management roles throughout the globe, working with both start-ups and multinationals alike. Prior to joining AOTI, Dr. Griffiths was the co-founder and CEO of eVent Medical Ltd., a start-up venture in the critical care ventilation field, which was sold to the Kobayashi pharmaceutical company of Japan. Preceding eVent, Dr. Griffiths held various senior management positions at Mallinckrodt Inc., Nellcor Puritan Bennett Inc., and Hudson RCI, amongst others.

    ... read more

    Mike Griffiths

    CEO & President
    Advanced Oxygen Therapy Inc

    Dr. Griffiths has worked in the critical and wound care fields for over three decades. He is a Fellow of both the Royal Society of Medicine and Chartered Management Institute. He holds a Doctorate from Middlesex University, London, United Kingdom, a post-graduate Diploma in Management from Kingston University, United Kingdom, and several further engineering and clinical credentials, including that of a Certified Respiratory Therapist.

    Dr. Griffiths is also a seasoned medical device executive who has been the CEO, President and Co-Founder of AOTI, since 2006. He brings his years of experience gained from a wide variety of management roles throughout the globe, working with both start-ups and multinationals alike. Prior to joining AOTI, Dr. Griffiths was the co-founder and CEO of eVent Medical Ltd., a start-up venture in the critical care ventilation field, which was sold to the Kobayashi pharmaceutical company of Japan. Preceding eVent, Dr. Griffiths held various senior management positions at Mallinckrodt Inc., Nellcor Puritan Bennett Inc., and Hudson RCI, amongst others.

  •

    Author:

    Kevin Richardson

    Chief Strategic Officer
    SANUWAVE
    ... read more

    Kevin Richardson

    Chief Strategic Officer
    SANUWAVE

  • Author:

    Julie Morabito

    Assistant Director
    FDA

    Assistant Director, Division of Infection Control and Plastic and Reconstructive Surgery at FDA’s Center for Devices and Radiological Health (CDRH). (Plastic Surgery Skin and Wound Devices Team).

    ... read more

    Julie Morabito

    Assistant Director
    FDA

    Assistant Director, Division of Infection Control and Plastic and Reconstructive Surgery at FDA’s Center for Devices and Radiological Health (CDRH). (Plastic Surgery Skin and Wound Devices Team).

  •

    Author:

    Jaideep Banerjee

    Lead Medical Science Liaisons and Clinical Strategy
    Smith & Nephew
    ... read more

    Jaideep Banerjee

    Lead Medical Science Liaisons and Clinical Strategy
    Smith & Nephew

  • Author:

    Laurent Decory

    COO
    Aurealis Therapeutics
    ... read more

    Laurent Decory

    COO
    Aurealis Therapeutics

  • Author:

    Artem Trotsyuk

    Venture Partner
    LongeVC
    ... read more

    Artem Trotsyuk

    Venture Partner
    LongeVC

  • Author:

    Ira Herman

    Co-Founder
    Precision Healing
    ... read more

    Ira Herman

    Co-Founder
    Precision Healing

  • Author:

    Kent Nielsen

    Principal Scientist, New Business Development
    Molnlycke
    ... read more

    Kent Nielsen

    Principal Scientist, New Business Development
    Molnlycke

  • Author:

    Thomas Serena

    Founder & CEO
    SerenaGroup

    Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School.

    To date he has opened and operates wound care centers across the United Sates and globally. Dr. Serena has been the lead or Principal investigator in over 100 clinical trials, including gene therapy for critical limb ischemia, antimicrobial dressings, growth factors, topical and parenteral antibiotics and CTP therapy. He founded the first wound healing cooperative research group that produced more than 12 manuscripts in 2016 alone. In 2011 he developed a diagnostic technique that now bears his name (The Serena Technique©). He holds numerous patents on wound care devices and dressings.

    He is recognized internationally as an expert in the field of wound healing: He has more than 200 published papers and has given more than 1000 invited lectures throughout the world. He has published three medical textbooks and authored numerous book chapters. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association.

    Dr. Serena has done extensive medical relief work with Health Volunteers Overseas and served as chairman of the AAWC Global Volunteers/HVO Steering Committee until 2016. In 2016 in partnership with HEAL Foundation he opened a wound clinic in Ho Chi Minh, Vietnam. Outside of wound healing, he consulted for the government of Rwanda on AIDS prevention research.

    ... read more

    Thomas Serena

    Founder & CEO
    SerenaGroup

    Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School.

    To date he has opened and operates wound care centers across the United Sates and globally. Dr. Serena has been the lead or Principal investigator in over 100 clinical trials, including gene therapy for critical limb ischemia, antimicrobial dressings, growth factors, topical and parenteral antibiotics and CTP therapy. He founded the first wound healing cooperative research group that produced more than 12 manuscripts in 2016 alone. In 2011 he developed a diagnostic technique that now bears his name (The Serena Technique©). He holds numerous patents on wound care devices and dressings.

    He is recognized internationally as an expert in the field of wound healing: He has more than 200 published papers and has given more than 1000 invited lectures throughout the world. He has published three medical textbooks and authored numerous book chapters. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association.

    Dr. Serena has done extensive medical relief work with Health Volunteers Overseas and served as chairman of the AAWC Global Volunteers/HVO Steering Committee until 2016. In 2016 in partnership with HEAL Foundation he opened a wound clinic in Ho Chi Minh, Vietnam. Outside of wound healing, he consulted for the government of Rwanda on AIDS prevention research.

  •

    Author:

    Amay Bandodkar

    Assistant Professor
    North Carolina State University
    ... read more

    Amay Bandodkar

    Assistant Professor
    North Carolina State University

  • Author:

    Howard Rosing, MD, PhD

    CEO, Co-Inventor
    Comfort Release

    Dr. Rosing is a Board Certified Physician and was instrumental in seeing the need and designing the new adhesive, that is called Comfort Release®.

    ... read more

    Howard Rosing, MD, PhD

    CEO, Co-Inventor
    Comfort Release

    Dr. Rosing is a Board Certified Physician and was instrumental in seeing the need and designing the new adhesive, that is called Comfort Release®.

  •

    Author:

    Caroline Fife

    CMO
    Intellicure
    ... read more

    Caroline Fife

    CMO
    Intellicure

  • Author:

    Jens Kirsch

    CEO
    Terraplasma Medical
    ... read more

    Jens Kirsch

    CEO
    Terraplasma Medical

  • Author:

    Ankit Agarwal

    Founder & CSO
    Imbed Biosciences Inc.
    ... read more

    Ankit Agarwal

    Founder & CSO
    Imbed Biosciences Inc.

  • Author:

    Jon Bloom

    CEO
    Podimetrics
    ... read more

    Jon Bloom

    CEO
    Podimetrics

  • Author:

    Dan Holsworth

    CEO
    Eluciderm
    ... read more

    Dan Holsworth

    CEO
    Eluciderm

  • Author:

    Jason Hanft

    CEO & Founder
    Defender
    ... read more

    Jason Hanft

    CEO & Founder
    Defender

  • Author:

    Dr. Jon Volmer

    Senior Director of Research Biology and Innovation
    MedPharm

    Jon Volmer joined MedPharm in 2016 to generate new technologies, systems, and biological models to expand MedPharm’s capabilities to better serve the needs of current clients, and expand into new areas of expertise. He has over 15 years’ experience developing a variety of biological models and technological lab support equipment in fields including immunology, microbiology, pulmonary disease, and mechanical modeling. Dr Volmer received his PhD on the biochemical basis of inflammatory remodeling in the lung from the University of Texas Graduate School of Biomedical Sciences

    ... read more

    Dr. Jon Volmer

    Senior Director of Research Biology and Innovation
    MedPharm

    Jon Volmer joined MedPharm in 2016 to generate new technologies, systems, and biological models to expand MedPharm’s capabilities to better serve the needs of current clients, and expand into new areas of expertise. He has over 15 years’ experience developing a variety of biological models and technological lab support equipment in fields including immunology, microbiology, pulmonary disease, and mechanical modeling. Dr Volmer received his PhD on the biochemical basis of inflammatory remodeling in the lung from the University of Texas Graduate School of Biomedical Sciences

  •

    Author:

    Jodie Giordano

    Biomedical Engineer
    FDA
    ... read more

    Jodie Giordano

    Biomedical Engineer
    FDA

  • Author:

    Vickie Driver

    System Chief
    INOVA Wound Healing and Hyperbaric Medicine Centre
    ... read more

    Vickie Driver

    System Chief
    INOVA Wound Healing and Hyperbaric Medicine Centre

  • Author:

    Emma Wright

    CMO
    Mölnlycke

    Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

    ... read more

    Emma Wright

    CMO
    Mölnlycke

    Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

  •

    Author:

    Ibraheem Badejo

    Senior R&D Director, External Front End Innovation
    Johnson & Johnson

    Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

    From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

    During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

    Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending

    ... read more

    Ibraheem Badejo

    Senior R&D Director, External Front End Innovation
    Johnson & Johnson

    Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

    From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

    During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

    Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending

  •

    Author:

    Monique Rennie

    Global Director, Medical Affairs
    Mölnlycke
    ... read more

    Monique Rennie

    Global Director, Medical Affairs
    Mölnlycke

  • Author:

    Micaela Gray

    Medical Affairs Manager
    Moleculight
    ... read more

    Micaela Gray

    Medical Affairs Manager
    Moleculight

  • Author:

    Carolina Wuesthoff

    Global Manager Medical Engagement & Communications
    Moleculight
    ... read more

    Carolina Wuesthoff

    Global Manager Medical Engagement & Communications
    Moleculight

  • Author:

    Kris Kieswetter

    Senior Director, Research and Technology
    3M
    ... read more

    Kris Kieswetter

    Senior Director, Research and Technology
    3M

  • Author:

    Haofan (Eric) Peng

    Lead Reviewer
    FDA
    ... read more

    Haofan (Eric) Peng

    Lead Reviewer
    FDA

  • Author:

    Macey Johnson

    Director Reimbursement & Market Access
    MolecuLight
    ... read more

    Macey Johnson

    Director Reimbursement & Market Access
    MolecuLight

  • Author:

    Michael Anselmo

    VP of Reimbursement, Health Economics & Market Access
    MCRA
    ... read more

    Michael Anselmo

    VP of Reimbursement, Health Economics & Market Access
    MCRA

  • Author:

    Susan Paquet

    VP & General Manager
    SmartTRAK
    ... read more

    Susan Paquet

    VP & General Manager
    SmartTRAK

  • Author:

    Greg Schultz

    Professor
    University of Florida
    ... read more

    Greg Schultz

    Professor
    University of Florida

  • Author:

    Hamid Khoja

    Chief Scientific Officer
    Fibrobiologics
    ... read more

    Hamid Khoja

    Chief Scientific Officer
    Fibrobiologics

  • Author:

    David Navazio

    Founder & President
    Gentell
    ... read more

    David Navazio

    Founder & President
    Gentell

  • Author:

    Kathleen Schaum

    President
    Kathleen D. Schaum & Associates
    ... read more

    Kathleen Schaum

    President
    Kathleen D. Schaum & Associates

  • Author:

    Windy Cole

    Director of Wound Care Research
    Kent State University College of Podiatric Medicine
    ... read more

    Windy Cole

    Director of Wound Care Research
    Kent State University College of Podiatric Medicine

  • Author:

    Mart Roosimaa

    Medical Science Liaison
    Nanordica
    ... read more

    Mart Roosimaa

    Medical Science Liaison
    Nanordica

  • Author:

    Thomas Busby

    Director
    Outcome Capital
    ... read more

    Thomas Busby

    Director
    Outcome Capital